Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation

Journal of Hepatology

Volumn 52, Issue 5, 2010, Pages 672-680

  Fukuhara, Takasuke ^a   Taketomi, Akinobu ^a   Okano, Shinji ^a   Ikegami, Toru ^a   Soejima, Yuji ^a   Shirabe, Ken ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Genetic mutation; Hepatitis C virus; Interferon; Liver transplantation; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIRAL GENETICS;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG TOLERANCE; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERONS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MUTATION; POLYETHYLENE GLYCOLS; RIBAVIRIN; TISSUE DONORS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 77951620946     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.10.034     Document Type: Article

References (29)

1. Manns M.P., Mchutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
2. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44 (2006) 97-101
3. Brown Jr. R.S. Hepatitis C and liver transplantation. Nature 436 (2005) 973-978
4. Marubashi S., Dono K., Miyamoto A., Takeda Y., Nagano H., Umeshita K., et al. Liver transplantation for hepatitis C. J Hepatobiliary Pancreat Surg 13 (2006) 382-392
5. Neumann U.P., Berg T., Bahra M., Puhl G., Gucklberger O., Langrehr J.N., et al. Long-term outcome of liver transplantation for chronic hepatitis C: a 10-year follow-up. Transplantation 77 (2004) 226-231
6. Mazzaferro V., Regalla E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
7. Freeman Jr. R.B. Transplantation for hepatocellular carcinoma: the Milan criteria and beyond. Liver Transpl 12 (2006) 8-13
8. Neumann U.P., Berg T., Bahra M., Seehofer D., Langrehr J.M., Neuhaus R., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41 (2004) 830-836
9. Veldt B.J., Poterucha J.J., Watt K.D.S., Wiesner R.H., Hay J.E., Kremers W.K., et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transpl 8 (2008) 2426-2433
10. Berardi S., Lodato F., Gramenzi A., D'Errico A., Lenzi M., Bontadini A., et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis. Gut 56 (2007) 237-242
11. Salomon J.A., Weinstein M.C., Hammitt J.K., and Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290 (2003) 228-237
12. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79 (2007) 1686-1695
13. Enomoto N., Sakura I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334 (1996) 77-81
14. El-Shammy A., Nagano-Fujii M., Sasase N., Imoto S., Kim S.R., and Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination threrapy. Hepatology 48 (2008) 38-47
15. Soejima Y., Taketomi A., Yoshizumi T., Uchiyama H., Harada N., Ijichi H., et al. Feasibility of left lobe living donor liver transplantation between adults: an 8-year, single-center experience of 107 cases. Am J Transpl 6 (2006) 1004-1011
16. Kurosaki M., Enomoto N., Murakami T., Sakuma I., Asahina Y., Yamamoto C., et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 25 (1997) 750-753
17. Sarrazin C., Berg T., Lee J.H., Teuber G., Dietrich C.F., Roth W.K., et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C type 1b undergoing combination therapy. J Hepatol 30 (1999) 1004-1013
18. Gale Jr. M.J., Korth M.J., Tang N.M., Tan S.L., Hopkins D.A., Dever T.E., et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230 (1997) 217-227
19. Noguchi T., Satoh S., Noshi T., Hatada E., Fukuda R., Kawai A., et al. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol Immunol 45 (2001) 829-840
20. Lyra A.C., Fan X., Lang D.M., Yusim K., Ramrakhiani S., Brunt E.M., et al. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 123 (2002) 1485-1493
21. Schvoerer E., Soulier E., Royer C., Renaudin A.C., Thumann C., Fafi-Kremer S., et al. Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. J Infect Dis 196 (2007) 528-536
22. Feliu A., Carrion J.A., Massaguer A., Martinez-bauer E., Garcia-Retortillo M., Gonzalez P., et al. Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. J Viral Hepat 13 (2006) 544-551
23. Berenguer M. Systemic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 49 (2008) 274-287
24. Oton E., Barcena R., Moreno-Planas J.M., Cuevas-Mons V., Moreno-Zamora A., Barrios C., et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. Am J Transpl 6 (2006) 2348-2355
25. Picciotto F.P., Tritto G., Lanza A.G., Addario L., Luca M.D., DiCostanzo G.G., et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 46 (2007) 459-465
26. Sharma P., Marrero J.A., Fontana R.J., Greenson J.K., Conjeevaram H., Su G.L., et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 13 (2007) 1100-1108
27. Weston S.J., Leistikow R.L., Reddy K.R., Torres M., Wertheimer A.M., Lewinsohn D.M., et al. Reconstruction of hepatitis C virus-specific T-cell-mediated immunity after liver transplantation. Hepatology 41 (2005) 72-81
28. Su X., Yee L.J., Im K.A., Rhodes S.L., Tang Y.M., Tong X., et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 49 (2008) 184-191
29. Kuo A., and Terrault N.A. Management of hepatitis C in liver transplant recipients. Am J Transpl 6 (2006) 449-458